Immusoft Announces FDA Clearance Of IND Application For ISP-001 For MPS I, The First Engineered B Cell Therapy To Enter Into Clinical Trials

Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, announced that the US FDA has cleared the Investigational New Drug Application (IND) for ISP-001 in the treatment of Mucopolysaccharidosis type I (MPS I).